Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Closings
1 closing/delay reported.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Summit Therapeu ADR
(NQ:
SMMT
)
24.39
+1.23 (+5.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeu ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Via
AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge.
Via
News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
September 19, 2024
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study.
Via
The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
There's a lot of hope for ivonescimab, but are investors being a bit too bullish?
Via
The Motley Fool
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
September 13, 2024
Via
Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
September 11, 2024
Via
Benzinga
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.
Via
Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...
Via
Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
September 17, 2024
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
September 16, 2024
Via
Benzinga
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
September 16, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
September 15, 2024
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.
Via
Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
September 14, 2024
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
Via
The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
September 13, 2024
Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers.
Via
The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
September 12, 2024
This high-flying biotech stock is moving even higher -- and for good reason.
Via
The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
September 12, 2024
Via
Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
September 12, 2024
The company is adding onto its success outperforming Merck's top drug in lung cancer patients.
Via
Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
September 12, 2024
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab.
Via
MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
September 12, 2024
Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net proceeds.
Via
Benzinga
Summit Therapeutics Raises $235 Million
September 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Is Summit Therapeutics a Buy Now?
September 10, 2024
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.
Via
The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.
Via
The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
September 09, 2024
Via
Benzinga
Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
September 09, 2024
Via
Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
September 09, 2024
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%.
Via
Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
September 09, 2024
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,...
Via
Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
September 08, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
August 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.